Page 13 - Activating Construct News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Activating construct. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Activating Construct Today - Breaking & Trending Today

"The Buzz" Show: Harpoon Therapeutics (NASDAQ: HARP) Interim Data From Multiple Myeloma Trial

"The Buzz" Show: Harpoon Therapeutics (NASDAQ: HARP) Interim Data From Multiple Myeloma Trial
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.

United States , American Society Of Hematology , Harpoon Therapeutics Inc , Buzz Show , Featuing Our Corporate News Recap , Interim Data From , Refractory Multiple Myeloma , American Society , Annual Meeting , Activating Construct , Harpoon Therapeutics ,

Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma

Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United States , Roberth Uhl , Exchange Commission , American Society Of Hematology , Harpoon Therapeutics Inc , Harpoon Therapeutics , American Society , Annual Meeting , Activating Construct , Conference Call , Fast Track , Private Securities Litigation Reform Act , Harpoon Therapeutic ,

Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma

11.12.2022 - Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma77% (10/13) objective response rate (ORR) observed across highest doses (12 and 24 mg) Responses . Seite 1 ....

United States , American Society Of Hematology , Harpoon Therapeutics Inc , American Society , Annual Meeting , Activating Construct ,

Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer

Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Westwickeroberth Uhlmanaging , Luke Walker , Julie Eastland , Harpoon Therapeutics Inc , University Of Oklahoma Health Sciences Center , Global Development , Seagen Inc , Exchange Commission , Oncology At Oregon Health Sciences University , Clinical Development , Wall Street , Chief Medical , Harpoon Therapeutics , Harpoon Therapeutic President , Chief Executive Officer , Vice President , Global Development Lead , Cascadian Therapeutics , Medical Degree , Oklahoma Health Sciences Center , Medical Oncology , Oregon Health Sciences , Nasdaq Listing Rule , Activating Construct , Private Securities Litigation Reform Act , Harpoon Therapeutic ,

Harpoon Therapeutics to Participate in Three Upcoming Investor Conferences

Harpoon Therapeutics to Participate in Three Upcoming Investor Conferences
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Robert Uhlicr Westwicke , Exchange Commission , Harpoon Therapeutics Inc , Annual Biopharma Conference , Annual Global Investment Conference , Healthcare Conference , Harpoon Therapeutics , Activating Construct , Private Securities Litigation Reform Act , Harpoon Therapeutic ,